B. Meignier

发表

Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.

R. Longnecker, B. Roizman, A. Sears, 1988, Virology.

Herpes simplex virus 1 mutant deleted in the alpha 22 gene: growth and gene expression in permissive and restrictive cells and establishment of latency in mice

B. Roizman, I. Halliburton, A. Sears, 1985, Journal of virology.

Highly attenuated poxvirus vectors.

M. Perkus, E. Paoletti, W. Cox, 1992, AIDS research and human retroviruses.

Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.

E. Paoletti, J. Tartaglia, J. Taylor, 1995, Developments in biological standardization.

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.

B. Autran, M. Kieny, J. Excler, 1995, AIDS research and human retroviruses.

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

E. Paoletti, Jill Taylor, J. Tartaglia, 1995, Vaccine.

Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.

R. Drillien, J. Crance, D. Garin, 2007, Vaccine.

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses

R. Webster, E. Govorkova, G. Murti, 1996, Journal of virology.

Genetically engineered attenuated herpes simplex viruses.

B. Meignier, 1991, Reviews of infectious diseases.

Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero).

R. Webster, L. Gubareva, E. Govorkova, 1995, The Journal of infectious diseases.

Herpes simplex vaccines.

R. Whitley, B. Meignier, 1992, Biotechnology.

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus).

B. Roizman, R. Whitley, B. Martín, 1990, The Journal of infectious diseases.

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents.

R. Longnecker, B. Roizman, B. Meignier, 1988, The Journal of infectious diseases.

Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.

B. Roizman, T. Jourdier, L. Pereira, 1987, The Journal of infectious diseases.

Colonization of murine ganglia by a superinfecting strain of herpes simplex virus

B. Roizman, B. Norrild, B. Meignier, 1983, Infection and immunity.

Herpes Simplex Virus 1 Mutant Deleted in the (x22 Gene: Growth

I. Halliburton, A. Sears, B. Meignier, 2022 .

Characterization of Vero cell growth and death in bioreactor with serum-containing and serum-free media

J. Marvel, A. Marc, C. Gerdil, 2001, Cytotechnology.

The safety and use of canarypox vectored vaccines.

E. Paoletti, J. Tartaglia, J. Excler, 1995, Developments in biological standardization.

NYVAC: a highly attenuated strain of vaccinia virus.

M. Perkus, S. Davis, E. Paoletti, 1992, Virology.

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.

W. Ho, S. Plotkin, S. Starr, 1990, Vaccine.

Immunisation with canarypox virus expressing rabies glycoprotein

E. Paoletti, J. Tartaglia, S. Plotkin, 1992, The Lancet.

Herpes simplex virus vaccines.

B. Roizman, B. Meignier, 1985, Antiviral research.

Establishment of latency in mice by herpes simplex virus 1 recombinants that carry insertions affecting regulation of the thymidine kinase gene

B. Roizman, A. Sears, B. Meignier, 1985, Journal of virology.

Genetic engineering and properties of novel herpes simplex viruses for use as potential vaccines and as vectors of foreign genes.

B. Roizman, B. Meignier, 1989, Advances in experimental medicine and biology.

Herpes Simplex Virus 1Mutant Deleted inthe(x22 Gene:Growth andGeneExpression inPermissive andRestrictive Cells and Establishment ofLatency inMice

S. Silver, B. Meignier, 1985 .

Vaccination against Herpes Simplex Virus Infections

B. Meignier, 1985 .

Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain

P. Fultz, F. Barré-Sinoussi, E. Muchmore, 1996, Journal of virology.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1

M. Kieny, P. Fultz, F. Barré-Sinoussi, 1995, Journal of virology.

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.

J. Tartaglia, R. El Habib, J. Excler, 1998, AIDS research and human retroviruses.

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.

E. Paoletti, J. Tartaglia, L. Fries, 1996, Vaccine.

Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium

J. Marvel, A. Marc, C. Gerdil, 2003, Cytotechnology.

Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

E. Paoletti, P. Fultz, F. Barré-Sinoussi, 1997, Virology.

Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.

M. Kieny, J. Tartaglia, C. Leclerc, 1997, AIDS research and human retroviruses.

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

M. Kieny, J. Excler, T. Matthews, 1995, AIDS research and human retroviruses.

Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.

P. Fultz, F. Barré-Sinoussi, C. Leclerc, 1998, AIDS research and human retroviruses.

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection

B. Autran, J. Tartaglia, P. Chong, 1999 .

Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice.

J. Chapsal, B. Meignier, F. Vaux-Peretz, 1992, Vaccine.

Application of molecular genetics to the design of live herpes simplex virus vaccines.

B. Roizman, B. Norrild, C. Thuning, 1982, Developments in biological standardization.

Immunization against viral infections associated with human cancer: The promise of modern biotechnology

B. Roizman, B. Meignier, 1988, CA: a cancer journal for clinicians.

Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus.

B. Meignier, F. Vaux-Peretz, 1990, Vaccine.

Establishment ofLatency inMicebyHerpesSimplex Virus 1 Recombinants ThatCarryInsertions Affecting Regulation ofthe Thymidine Kinase Gene

B. Meignier, 1985 .

Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses.

É. Gönczöl, S. Plotkin, K. Berencsi, 1994, Laboratory investigation; a journal of technical methods and pathology.

Failure to induce cervical cancer in mice by long‐term frequent vaginal exposure to live or inactivated herpes simplex viruses

F. Rapp, B. Roizman, N. Frenkel, 1986, International journal of cancer.

Antiplatelet antibodies during the course of HIV-preventive vaccine trial.

M. Kieny, M. Morel-Kopp, J. Excler, 1996, AIDS.

Analyses of transplanted murine tumors for HSV DNA sequences

F. Rapp, F. Yehiely, B. Roizman, 1986, International Journal of Cancer.